|
US7270971B2
(en)
*
|
2003-10-16 |
2007-09-18 |
Merck & Co., Inc. |
Fluorescence assay for measuring the rate of cholesterol ester transfer
|
|
DOP2005000123A
(es)
|
2004-07-02 |
2011-07-15 |
Merck Sharp & Dohme |
Inhibidores de cetp
|
|
CN102757397A
(zh)
*
|
2005-07-01 |
2012-10-31 |
默沙东公司 |
合成cetp抑制剂的方法
|
|
US8486983B2
(en)
*
|
2005-12-05 |
2013-07-16 |
Merck Sharp & Dohme Corp. |
Self-emulsifying formulations of CETP inhibitors
|
|
TW200732313A
(en)
*
|
2005-12-15 |
2007-09-01 |
Astrazeneca Ab |
Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
|
|
EP1973889B1
(en)
*
|
2005-12-30 |
2016-08-24 |
Merck Sharp & Dohme Corp. |
Cetp inhibitors
|
|
WO2007081570A2
(en)
*
|
2005-12-30 |
2007-07-19 |
Merck & Co., Inc. |
Cholesteryl ester transfer protein inhibitors
|
|
NZ568904A
(en)
*
|
2005-12-30 |
2011-05-27 |
Merck Sharp & Dohme |
1,3-oxazolidin-2-one derivatives useful as CETP inhibitors
|
|
EP1971595B1
(en)
*
|
2005-12-30 |
2013-10-16 |
Merck Sharp & Dohme Corp. |
Cetp inhibitors
|
|
WO2007092642A2
(en)
*
|
2006-02-09 |
2007-08-16 |
Merck & Co., Inc. |
Polymer formulations of cetp inhibitors
|
|
US8383660B2
(en)
*
|
2006-03-10 |
2013-02-26 |
Pfizer Inc. |
Dibenzyl amine compounds and derivatives
|
|
US7919506B2
(en)
*
|
2006-03-10 |
2011-04-05 |
Pfizer Inc. |
Dibenzyl amine compounds and derivatives
|
|
WO2007136672A2
(en)
*
|
2006-05-19 |
2007-11-29 |
Merck & Co., Inc. |
Synthesis of a biaryl synthetic intermediate
|
|
WO2008082567A1
(en)
*
|
2006-12-29 |
2008-07-10 |
Merck & Co., Inc. |
Process for synthesizing a cetp inhibitor
|
|
NZ600947A
(en)
|
2007-01-26 |
2012-12-21 |
Kaneq Pharma Inc |
Fused Aromatic Difluoromethanephosphonates as Protein Tyrosine Phosphatase 1B (PTP-1B) Inhibitors
|
|
CA2681628C
(en)
|
2007-03-16 |
2016-10-18 |
Concert Pharmaceuticals, Inc. |
Inhibitors of cholesterol ester transfer protein
|
|
AU2008248186B2
(en)
|
2007-05-07 |
2014-02-06 |
Merck Sharp & Dohme Corp. |
Method of treatment using fused aromatic compounds having anti-diabetic activity
|
|
MX2009013332A
(es)
|
2007-06-08 |
2010-01-25 |
Mannkind Corp |
Inhibidores de ire-1 alfa.
|
|
EP2166847B1
(en)
*
|
2007-06-20 |
2014-11-19 |
Merck Sharp & Dohme Corp. |
Cetp inhibitors derived from benzoxazole arylamides
|
|
CA2689523A1
(en)
*
|
2007-06-20 |
2008-12-24 |
Merck Sharp & Dohme Corp. |
Cetp inhibitors derived from benzoxazole arylamides
|
|
WO2008156715A1
(en)
*
|
2007-06-20 |
2008-12-24 |
Merck & Co., Inc. |
Cetp inhibitors derived from benzoxazole arylamides
|
|
CA2691662A1
(en)
|
2007-07-02 |
2009-01-08 |
F. Hoffmann-La Roche Ag |
Imidazole derivatives as ccr2 receptor antagonists
|
|
JP5470557B2
(ja)
*
|
2007-07-26 |
2014-04-16 |
ヴァイティー ファーマシューティカルズ，インコーポレイテッド |
１１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤の合成
|
|
AR069207A1
(es)
*
|
2007-11-07 |
2010-01-06 |
Vitae Pharmaceuticals Inc |
Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
|
|
US8440658B2
(en)
|
2007-12-11 |
2013-05-14 |
Vitae Pharmaceuticals, Inc. |
Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
|
|
TW200934490A
(en)
*
|
2008-01-07 |
2009-08-16 |
Vitae Pharmaceuticals Inc |
Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
|
|
WO2009094169A1
(en)
*
|
2008-01-24 |
2009-07-30 |
Vitae Pharmaceuticals, Inc. |
Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1
|
|
BRPI0907364A2
(pt)
*
|
2008-02-01 |
2015-07-14 |
Amira Pharmaceuticals Inc |
Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina
|
|
WO2009099901A1
(en)
*
|
2008-02-01 |
2009-08-13 |
Amira Pharmaceuticals, Inc. |
N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
|
|
CA2714532A1
(en)
*
|
2008-02-11 |
2009-08-20 |
Vitae Pharmaceuticals, Inc. |
1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
|
|
WO2009102893A2
(en)
|
2008-02-14 |
2009-08-20 |
Amira Pharmaceuticals, Inc. |
CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors
|
|
US8598160B2
(en)
*
|
2008-02-15 |
2013-12-03 |
Vitae Pharmaceuticals, Inc. |
Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
|
|
JP2011513242A
(ja)
|
2008-02-25 |
2011-04-28 |
アミラ ファーマシューティカルズ，インク． |
プロスタグランジンｄ２受容体アンタゴニスト
|
|
WO2009117109A1
(en)
*
|
2008-03-18 |
2009-09-24 |
Vitae Pharmaceuticals, Inc. |
Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
|
|
US8426449B2
(en)
|
2008-04-02 |
2013-04-23 |
Panmira Pharmaceuticals, Llc |
Aminoalkylphenyl antagonists of prostaglandin D2 receptors
|
|
EP2291370B1
(en)
|
2008-05-01 |
2013-11-27 |
Vitae Pharmaceuticals, Inc. |
Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
|
|
JP5696037B2
(ja)
|
2008-05-01 |
2015-04-08 |
ヴァイティー ファーマシューティカルズ，インコーポレイテッド |
１１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター
|
|
RU2531272C2
(ru)
|
2008-05-01 |
2014-10-20 |
Вайтаи Фармасьютиклз, Инк. |
Циклические ингибиторы 11бета-гидроксистероид-дегидрогеназы 1
|
|
US8063088B2
(en)
*
|
2008-06-11 |
2011-11-22 |
Hoffmann-La Roche Inc. |
Imidazolidine derivatives
|
|
EP2323994A1
(en)
|
2008-07-25 |
2011-05-25 |
Boehringer Ingelheim International GmbH |
Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
|
|
NZ590495A
(en)
|
2008-07-25 |
2012-10-26 |
Vitae Pharmaceuticals Inc |
Dihydropyridin-phenyl-3-oxazinan-2-ones as inhibitors of 11beta-hydroxysteroid dehydrogenase 1
|
|
WO2010010157A2
(en)
|
2008-07-25 |
2010-01-28 |
Boehringer Ingelheim International Gmbh |
INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1
|
|
GB2463788B
(en)
|
2008-09-29 |
2010-12-15 |
Amira Pharmaceuticals Inc |
Heteroaryl antagonists of prostaglandin D2 receptors
|
|
DE102008049675A1
(de)
|
2008-09-30 |
2010-04-01 |
Markus Dr. Heinrich |
Verfahren zur Herstellung von 3-Aminobiphenylen
|
|
US8354454B2
(en)
*
|
2008-10-01 |
2013-01-15 |
Merck Sharp & Dohme Corp. |
Prodrugs of oxazolidinone CETP inhibitors
|
|
WO2010039977A2
(en)
|
2008-10-01 |
2010-04-08 |
Amira Pharmaceuticals, Inc. |
Heteroaryl antagonists of prostaglandin d2 receptors
|
|
WO2010042652A2
(en)
|
2008-10-08 |
2010-04-15 |
Amira Pharmaceuticals, Inc. |
Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
|
|
EP2348857B1
(en)
|
2008-10-22 |
2016-02-24 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
|
US8329914B2
(en)
|
2008-10-31 |
2012-12-11 |
Merck Sharp & Dohme Corp |
Cyclic benzimidazole derivatives useful as anti-diabetic agents
|
|
US8383654B2
(en)
|
2008-11-17 |
2013-02-26 |
Panmira Pharmaceuticals, Llc |
Heterocyclic antagonists of prostaglandin D2 receptors
|
|
TW201028414A
(en)
|
2009-01-16 |
2010-08-01 |
Merck Sharp & Dohme |
Oxadiazole beta carboline derivatives as antidiabetic compounds
|
|
JP2012515782A
(ja)
|
2009-01-23 |
2012-07-12 |
シェーリング コーポレイション |
抗糖尿病性架橋および縮合化合物
|
|
WO2010085525A1
(en)
|
2009-01-23 |
2010-07-29 |
Schering Corporation |
Bridged and fused heterocyclic antidiabetic compounds
|
|
JP5679997B2
(ja)
|
2009-02-04 |
2015-03-04 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
１１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
|
|
AR075051A1
(es)
|
2009-02-05 |
2011-03-02 |
Schering Corp |
Compuestos antidiabeticos que contienen ftalazina
|
|
US8680093B2
(en)
|
2009-04-30 |
2014-03-25 |
Vitae Pharmaceuticals, Inc. |
Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
|
|
US8927539B2
(en)
|
2009-06-11 |
2015-01-06 |
Vitae Pharmaceuticals, Inc. |
Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 based on the 1,3-oxazinan-2-one structure
|
|
EP2448928B1
(en)
|
2009-07-01 |
2014-08-13 |
Vitae Pharmaceuticals, Inc. |
Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
|
|
US8815917B2
(en)
*
|
2009-08-05 |
2014-08-26 |
Panmira Pharmaceuticals, Llc |
DP2 antagonist and uses thereof
|
|
JP2011057661A
(ja)
|
2009-08-14 |
2011-03-24 |
Bayer Cropscience Ag |
殺虫性カルボキサミド類
|
|
WO2011056737A1
(en)
|
2009-11-05 |
2011-05-12 |
Boehringer Ingelheim International Gmbh |
Novel chiral phosphorus ligands
|
|
WO2011088025A1
(en)
|
2010-01-15 |
2011-07-21 |
Merck Sharp & Dohme Corp. |
Oxadiazole beta carboline derivatives as antidiabetic compounds
|
|
JP2013520502A
(ja)
|
2010-02-25 |
2013-06-06 |
メルク・シャープ・エンド・ドーム・コーポレイション |
有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
|
|
EP2576570A1
(en)
|
2010-05-26 |
2013-04-10 |
Boehringer Ingelheim International GmbH |
2-oxo-1,2-dihydropyridin-4-ylboronic acid derivatives
|
|
EP2397473A1
(en)
|
2010-06-14 |
2011-12-21 |
LEK Pharmaceuticals d.d. |
A stable highly crystalline anacetrapib
|
|
WO2011159760A1
(en)
|
2010-06-16 |
2011-12-22 |
Vitae Pharmaceuticals, Inc. |
Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
|
|
WO2011161128A1
(en)
|
2010-06-25 |
2011-12-29 |
Boehringer Ingelheim International Gmbh |
Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
|
|
EP2626351A4
(en)
|
2010-10-04 |
2014-03-12 |
Kowa Co |
MEANS FOR INHIBITING THE EXPRESSION OF MRNA INVOLVED IN THE FAT REPLACEMENT
|
|
CN103269592B
(zh)
*
|
2010-10-29 |
2016-05-11 |
默沙东公司 |
环胺取代的噁唑烷酮cetp抑制剂
|
|
WO2012059416A1
(en)
|
2010-11-02 |
2012-05-10 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical combinations for the treatment of metabolic disorders
|
|
EP2468735A1
(en)
*
|
2010-12-23 |
2012-06-27 |
LEK Pharmaceuticals d.d. |
Synthesis of intermediates for preparing anacetrapib and derivates thereof
|
|
EP2468736A1
(en)
*
|
2010-12-23 |
2012-06-27 |
LEK Pharmaceuticals d.d. |
Synthesis of intermediates for preparing anacetrapib and derivates thereof
|
|
ES2648788T3
(es)
|
2011-01-26 |
2018-01-08 |
Inserm - Institut National De La Santé Et De La Recherche Médicale |
Método para evaluar el riesgo de un sujeto de tener una enfermedad cardiovascular
|
|
SG192941A1
(en)
|
2011-02-25 |
2013-09-30 |
Merck Sharp & Dohme |
Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
|
|
HRP20170422T1
(hr)
|
2011-04-12 |
2017-06-16 |
Chong Kun Dang Pharmaceutical Corp. |
3-(2-aril-cikloalkenilmetil)-oksazolidin-2-on derivati kao inhibitori transportnog proteina estera kolesterola (cetp)
|
|
CA2840985A1
(en)
*
|
2011-07-07 |
2013-01-10 |
Mochida Phamaceutical Co., Ltd. |
Anti-obesity agent comprising high-purity epa
|
|
SG10201605304VA
(en)
|
2011-07-08 |
2016-08-30 |
Novartis Ag |
Method of treating atherosclerosis in high triglyceride subjects
|
|
JO3210B1
(ar)
|
2011-10-28 |
2018-03-08 |
Merck Sharp & Dohme |
مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
|
|
US9145348B2
(en)
|
2011-10-31 |
2015-09-29 |
Merck Sharpe & Dohme Corp. |
Process for synthesizing a CETP inhibitor
|
|
WO2013064188A1
(en)
|
2011-11-03 |
2013-05-10 |
Lek Pharmaceuticals D.D. |
A stable highly crystalline anacetrapib
|
|
WO2013080999A1
(ja)
|
2011-11-29 |
2013-06-06 |
興和株式会社 |
ＮＰＣ１Ｌ１及び／又はＬＩＰＧ ｍＲＮＡの発現抑制剤並びに肥満症の予防及び／又は治療剤
|
|
JP6030147B2
(ja)
*
|
2011-11-30 |
2016-11-24 |
デウン ファーマシューティカル カンパニー リミテッド |
高トリグリセリド血症または高トリグリセリド血症に関連する疾患を予防または治療するための医薬組成物
|
|
WO2013091696A1
(en)
*
|
2011-12-21 |
2013-06-27 |
Lek Pharmaceuticals D.D. |
Synthesis of intermediates for preparing anacetrapib and derivatives thereof
|
|
WO2013165854A1
(en)
*
|
2012-05-02 |
2013-11-07 |
Merck Sharp & Dohme Corp. |
Cyclic amine substituted heterocyclic cetp inhibitors
|
|
MX347400B
(es)
|
2012-06-29 |
2017-04-18 |
Univ Nac Autónoma De México |
Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.
|
|
WO2014012428A1
(zh)
*
|
2012-07-19 |
2014-01-23 |
上海恒瑞医药有限公司 |
噁唑烷酮类衍生物、其制备方法及其在医药上的应用
|
|
WO2014031465A1
(en)
|
2012-08-22 |
2014-02-27 |
Merck Sharp & Dohme Corp. |
Novel azabenzimidazole tetrahydropyran derivatives
|
|
EP2934518B1
(en)
|
2012-12-19 |
2020-02-19 |
Merck Sharp & Dohme Corp. |
Spirocyclic cetp inhibitors
|
|
WO2014099834A1
(en)
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Therapeutic thiazolidinone compounds
|
|
WO2014111953A1
(en)
*
|
2013-01-17 |
2014-07-24 |
Glenmark Pharmaceuticals Limited; Glenmark Generics Limited |
Process for preparation of anacetrapib and intermediates thereof
|
|
ES2642172T3
(es)
|
2013-01-31 |
2017-11-15 |
Chong Kun Dang Pharmaceutical Corp. |
Compuestos derivados de ciclohexeno sustituidos con biarilo o biarilo heterocíclico como inhibidores de CETP
|
|
WO2014139388A1
(en)
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
|
WO2015017302A2
(en)
|
2013-07-30 |
2015-02-05 |
Merck Sharp & Dohme Corp. |
Bicyclic ureas and thiadiazolidine-1,1-dioxides as cetp inhibitors
|
|
WO2015054088A1
(en)
|
2013-10-10 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
3,3'-disubstituted indolines as inhibitors of cholesterol ester transfer protein
|
|
CN105814064A
(zh)
|
2013-12-17 |
2016-07-27 |
默沙东公司 |
作为胆固醇酯转运蛋白的抑制剂的稠合双环异噁唑啉类
|
|
WO2015106674A1
(zh)
*
|
2014-01-14 |
2015-07-23 |
杭州普晒医药科技有限公司 |
一种安塞曲匹的晶型及其制备方法、其药物组合物和用途
|
|
CN103923030B
(zh)
*
|
2014-03-27 |
2015-07-22 |
汕头经济特区鮀滨制药厂 |
一种安塞曲匹的关键中间体的合成方法
|
|
CN103923031A
(zh)
*
|
2014-04-01 |
2014-07-16 |
汕头经济特区鮀滨制药厂 |
一种安塞曲匹的中间体的合成方法
|
|
EP3174537B1
(en)
|
2014-07-29 |
2021-06-23 |
Merck Sharp & Dohme Corp. |
Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein
|
|
MX384679B
(es)
|
2014-07-30 |
2025-03-14 |
Hoffmann La Roche |
Marcadores genéticos para predecir la reactividad a terapia con agente que eleva la lipoproteína de alta densidad (hdl) o que imita la lipoproteína de alta densidad (hdl).
|
|
CN104230835B
(zh)
*
|
2014-09-01 |
2017-01-25 |
福建师范大学 |
一种合成n‑苯乙烯基恶唑烷‑2‑酮衍生物的方法
|
|
WO2016067194A1
(en)
*
|
2014-10-27 |
2016-05-06 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of anacetrapib and an intermediate thereof
|
|
CN106032362B
(zh)
*
|
2015-03-10 |
2018-06-19 |
湖南千金湘江药业股份有限公司 |
安塞曲匹的制备方法
|
|
US20190152992A1
(en)
|
2016-06-29 |
2019-05-23 |
Orion Corporation |
Benzodioxane derivatives and their pharmaceutical use
|
|
KR101902002B1
(ko)
*
|
2016-07-19 |
2018-09-27 |
재단법인 대구경북첨단의료산업진흥재단 |
Cetp 억제제로서의 옥사졸리딘온 유도체 화합물
|
|
CN109563019A
(zh)
*
|
2016-08-17 |
2019-04-02 |
诺华股份有限公司 |
Nep抑制剂合成的新方法和中间体
|
|
CN106496154A
(zh)
*
|
2016-10-18 |
2017-03-15 |
湖南德魅信息技术有限公司 |
安塞曲匹的制备方法
|
|
CN106496211A
(zh)
*
|
2016-10-18 |
2017-03-15 |
湖南德魅信息技术有限公司 |
二氟甲基取代的噁唑烷酮化合物及其用途
|
|
CN106749075A
(zh)
*
|
2016-11-24 |
2017-05-31 |
山东新华制药股份有限公司 |
阿那曲波的恶唑烷酮中间体的晶型及其制备方法
|
|
US20190070178A1
(en)
|
2017-08-29 |
2019-03-07 |
Dalcor Pharma Uk Ltd., Stockport Zug Branch |
Methods for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events
|
|
JOP20180092A1
(ar)
|
2017-10-13 |
2019-04-13 |
Gilead Sciences Inc |
مثبطات hiv بروتياز
|
|
AU2019319089A1
(en)
|
2018-08-09 |
2021-02-25 |
Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch |
Methods for delaying occurrence of new-onset type 2 diabetes and for slowing progression of and treating type 2 diabetes
|
|
AU2020232350A1
(en)
|
2019-03-07 |
2021-07-29 |
Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch |
Methods for treating or preventing heart failure and reducing risk of heart failure
|
|
TW202104210A
(zh)
|
2019-04-17 |
2021-02-01 |
美商基利科學股份有限公司 |
Hiv蛋白酶抑制劑
|
|
EP3999518A2
(en)
|
2019-07-19 |
2022-05-25 |
Biosynth AG |
Method of making nicotinamide ribofuranoside salts, nicotinamide ribofuranoside salts as such, and uses thereof
|
|
EP4146205A4
(en)
|
2020-05-05 |
2024-05-29 |
Nuvalent, Inc. |
HETEROAROMATIC MACROCYCLIC ETHERS AS CHEMOTHERAPEUTIC AGENTS
|
|
IL297832A
(en)
|
2020-05-05 |
2023-01-01 |
Nuvalent Inc |
Macrocyclic heteroaromatic chemotherapeutic agents
|
|
KR102651062B1
(ko)
*
|
2020-10-08 |
2024-03-25 |
재단법인 대구경북첨단의료산업진흥재단 |
Pcsk9 억제제로서 아미노알콜 유도체 및 이를 함유하는 고콜레스테롤 혈증의 예방 또는 치료용 약학적 조성물
|
|
EP4362933A4
(en)
*
|
2021-06-30 |
2025-06-04 |
Apellis Pharmaceuticals, Inc. |
COMPLEMENT INHIBITION
|
|
TW202320768A
(zh)
|
2021-10-01 |
2023-06-01 |
美商努法倫特公司 |
雜芳族大環醚化合物之固體形式、醫藥組成物及製備
|
|
WO2025093129A1
(en)
|
2023-11-01 |
2025-05-08 |
Newamsterdam Pharma B.V. |
Treatment and prevention of age-related macular degeneration using a cetp inhibitor
|